ClinicalTrials.gg
TerminatedNCT01606800START 4Updated Oct 25, 2018Results posted

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

A Phase 4 interventional study of PEG-IFN alfa-2b and ribavirin in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Why this study was terminated
The trial was terminated due to change in new standard of therapy during the study period.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
29th of 39
45 · median 99
Started
2013
with 2 others
Phase 4
10 of 40
none open now
Registered
36th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 29th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2013, is one of 10 in phase 4, and was the 36th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to assess the efficacy of a short course of therapy (24 weeks) versus standard 48 week treatment in previously untreated adult participants with chronic hepatitis C (CHC) genotype 4 infection who achieve rapid virologic response (RVR), defined as HCV ribonucleic acid (RNA) negativity after 4 weeks of treatment.

Read the detailed description

Participants who achieved RVR after 4 weeks of PEG-INF alfa-2b plus RBV treatment were randomized to receive either 20 or 44 weeks of continued therapy, for a total of 24 or 48 weeks total of PEG-INF plus RBV therapy.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is ≥40 kg and ≤120 kg weight
  • Participant and participant's partner(s) must each agree to use acceptable methods of for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations.
  • Previously documented CHC genotype 4 infection
  • Liver or fibrotest and fibroscan with histology consistent with CHC and no other etiology and with hepatic fibrosis scores (F0, F1, F2, F3).

Exclusion criteria

Exclusion Criteria:

  • Co-infected with the (HIV) or virus
  • Treatment for with any medication
  • Treatment with any investigational drug within 30 days of the screening visit
  • Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
  • hepatitis or a history of autoimmune disease
  • Hepatic fibrosis score F4
  • Severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months
  • Autoimmune hepatitis or a history of autoimmune disease
  • Thyroid disease uncontrolled with conventional treatment
  • Epilepsy and/or compromised central nervous system (CNS) function
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    44 Weeks of PEG-IFN alfa-2b + RBV

    Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.

    Drug: PEG-IFN alfa-2b · Drug: ribavirin

  • Experimental
    20 Weeks of PEG-IFN alfa-2b + RBV

    Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.

    Drug: PEG-IFN alfa-2b · Drug: ribavirin

Interventions

  • Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week

  • Ribavirin 200 mg capsules administered orally daily based on weight

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Sustained Virologic Response (SVR)

    SVR was defined as undetectable HCV RNA levels 24 weeks after the completion of therapy.

    Time frame: At 24 weeks after the completion of therapy (up to 72 weeks)

07

Results

Posted Feb 23, 2016
Limitations and caveats
This Trial was prematurely terminated due to the availability of more promising treatment for HCV participants and the change in treatment guidelines, which will offer the patient a better treatment opportunity.

Participant flow

Participant flow — Overall Study
Milestone44 Weeks of PEG-IFN Alfa-2b + RBV20 Weeks of PEG-IFN Alfa-2b + RBV
Started2223
Treated2223
Completed1721
Not completed52
Withdrew: Adverse event31
Withdrew: Participant withdrew consent01
Withdrew: Missing completion status20

Outcome measures

PrimaryNumber of Participants Achieving Sustained Virologic Response (SVR)

SVR was defined as undetectable HCV RNA levels 24 weeks after the completion of therapy.

Time frame:
At 24 weeks after the completion of therapy (up to 72 weeks)
Reported as:
Number · Participants
Number of Participants Achieving Sustained Virologic Response (SVR)
Participants44 Weeks of PEG-IFN Alfa-2b + RBV20 Weeks of PEG-IFN Alfa-2b + RBV
Number of Participants Achieving Sustained Virologic Response (SVR)1322

Adverse events

Collected over Up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
44 Weeks of PEG-IFN Alfa-2b + RBV—0/22 (0%)16/22 (72.7%)
20 Weeks of PEG-IFN Alfa-2b + RBV—2/23 (8.7%)13/23 (56.5%)
Most frequent serious events
Most frequent serious events
Event44 Weeks of PEG-IFN Alfa-2b + RBV20 Weeks of PEG-IFN Alfa-2b + RBV
AnemiaBlood and lymphatic system disorders0/221/23
LeukopaeniaBlood and lymphatic system disorders0/221/23
Most frequent other events
Showing 10 of 13
Most frequent other events
Event44 Weeks of PEG-IFN Alfa-2b + RBV20 Weeks of PEG-IFN Alfa-2b + RBV
AnemiaBlood and lymphatic system disorders5/222/23
FatigueGeneral disorders5/221/23
HeadacheNervous system disorders3/221/23
PruritusSkin and subcutaneous tissue disorders3/222/23
Vision blurredEye disorders2/221/23
Abdominal pain upperGastrointestinal disorders2/221/23
PyrexiaGeneral disorders2/220/23
Blood thyroid stimulating hormone increasedInvestigations2/222/23
Bone painMusculoskeletal and connective tissue disorders2/221/23
ArthralgiaMusculoskeletal and connective tissue disorders2/220/23

Baseline characteristics

All Treated Population, which included all participants who received at least one dose of study medication after RVR.

Age, Continuous
Age, Continuous(Years)44 Weeks of PEG-IFN Alfa-2b + RBV20 Weeks of PEG-IFN Alfa-2b + RBVTotal
Mean38.4 ± 10.7937.1 ± 11.2237.7 ± 10.91
Sex: Female, Male
Sex: Female, Male(Participants)44 Weeks of PEG-IFN Alfa-2b + RBV20 Weeks of PEG-IFN Alfa-2b + RBVTotal
Female91019
Male131326
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Jan 2015, 24 months.

Results were first posted in Feb 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2012
First posted
May 28, 2012
StartActual
Jan 1, 2013
Primary completionActual
Jan 26, 2015
CompletionActual
Jan 26, 2015
Results first posted
Feb 23, 2016
Last update
Oct 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01606800
Responsible party
Sponsor
First posted
May 28, 2012
Start date
Jan 1, 2013
Primary completion
Jan 26, 2015
Completion
Jan 26, 2015
Results posted
Feb 23, 2016
Last update
Oct 25, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion